Beaumont

Beaumont Laboratory

Dearborn • Farmington Hills • Grosse Pointe • Royal Oak • Taylor • Trenton • Troy • Wayne

Laboratory Bulletin

Hyperhomocysteinemia Genotyping for Thrombotic Risk Assessment (*MTHFR*)-Discontinued

Effective Date: January 24, 2022

Hyperhomocysteinemia (*MTHFR*) Genotyping for Thrombotic Risk Assessment has been discontinued by the manufacturer. The Beaumont Laboratory has had difficulty in procuring the supply of these test reagents. Additionally, testing recommendations for *MTHFR* mutations have evolved and the American College of Medical Genetics (ACMG) and American College of Obstetricians and Gynecologists (ACOG) recommend against testing.
Meta-analyses have disproven an association between hyperhomocysteinemia and risk for coronary heart disease and between MTHFR polymorphism status and risk for venous thromboembolism. Both ACOG and ACMG have stated that *MTHFR* polymorphism testing has minimal clinical utility and, therefore should not be ordered as a part of a routine evaluation for thrombophilia. Due to these factors the *MTHFR* genotyping will be discontinued.
Both Factor V Leiden (CPT Code: 81241) and Factor II (Prothrombin) (CPT Code: 81240) will continue to be offered at Beaumont Laboratory.

Test Discontinued:

Hyperhomocysteinemia Genotyping for Thrombotic Risk Assessment (Homocysteine genotyping, MTHFR genotyping, Hyperhomocysteinemia genotyping, Hyperhomocysteinemia (MTHFR) Genotyping).

- Test Code: LAB6386 CPT:81291

If you have questions, please contact please contact your Beaumont Laboratory Customer Service Department:

- Farmington Hills, Grosse Pointe, Royal Oak and Troy: 800-551-0488 or 248-551-1155, Option 5
- Dearborn, Taylor, Trenton and Wayne: 800-245-3725, Option 1

Laboratory Test Directory: http://beaumontlaboratory.com/test-lab-directory.

Date submitted: **January 21, 2022**
Submitted by: Mitual Amin, MD, Chair, System Medical Director, Anatomic Pathology
Susan Daraiseh, PhD, Technical Director, Molecular Pathology